Belgian biotechnology company Cardio3 BioSciences (C3BS), a specialist in the discovery and development of regenerative, protective and reconstructive therapies for the treatment of cardiac diseases, has hired Gaëtane Metz as Chief Operating Officer with a view to accelerating the industrialisation process and preparing the commercialisation of its leading product, C-Cure, which is being developed to treat heart failure.
Prior to joining C3BS, Dr Metz was Managing Director of the Life Sciences, Energy and Industry Division at Altran Europe. She has also held senior and management positions at CVO CyberConseil, and GlaxoSmithKline Biologicals, where she worked for 11 years.
Dr Metz holds a PhD in Bioengineering/Biomedical from the Free University of Brussels (ULB).